Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-24 23:39 | 2025-03-20 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $6.93 | 91 | $631 | 86,348 |
| 2025-03-25 00:45 | 2025-03-20 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $12.92 | 127,198 | $1,643,246 | 17,157,802 |
| 2025-03-24 16:00 | 2025-03-20 | FGEN | KYNTRA BIO, INC. | Schoeneck James A | Director | BUY | $0.35 | 300,000 | $105,030 | 373,722 |
| 2025-03-24 23:33 | 2025-03-21 | KURA | Kura Oncology, Inc. | Hasnain Faheem | Director | OPT+S | $8.00 | 22,682 | $181,456 | 23,983 |
| 2025-03-25 00:06 | 2025-03-20 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Tupper Colleen | Officer | SELL | $30.03 | 7,602 | $228,250 | 156,667 |
| 2025-03-25 00:05 | 2025-03-20 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dreyer Scott | Officer | SELL | $30.03 | 20,808 | $624,793 | 103,613 |
| 2025-03-25 00:47 | 2025-03-21 | RYTM | RHYTHM PHARMACEUTICALS, INC. | German Christopher Paul | Officer | OPT+S | $54.23 | 344 | $18,655 | 2,889 |
| 2025-03-21 23:53 | 2025-03-20 | CNTA | Centessa Pharmaceuticals plc | SAHA SAURABH | Director, Officer | SELL | $16.69 | 55,000 | $918,060 | 276,017 |
| 2025-03-22 03:03 | 2025-03-19 | IRON | Disc Medicine, Inc. | Ashiya Mona | Director | SELL | $54.02 | 52,429 | $2,831,989 | 187,297 |
| 2025-03-22 01:34 | 2025-03-19 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% owner | BUY | $0.42 | 45,000 | $19,053 | 358,522 |
| 2025-03-22 00:49 | 2025-03-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $20.61 | 12,500 | $257,575 | 1,002,688 |
| 2025-03-22 01:30 | 2025-03-20 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Officer | OPT+S | $14.00 | 10,000 | $140,000 | 7,696 |
| 2025-03-22 01:34 | 2025-03-19 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | SELL | $34.20 | 2,515 | $86,021 | 72,233 |
| 2025-03-22 01:33 | 2025-03-19 | CRNX | Crinetics Pharmaceuticals, Inc. | Knight Jeff E. | Officer | SELL | $34.20 | 7,162 | $244,964 | 87,491 |
| 2025-03-22 01:32 | 2025-03-19 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Officer | SELL | $34.20 | 5,770 | $197,353 | 108,588 |
| 2025-03-22 01:31 | 2025-03-19 | CRNX | Crinetics Pharmaceuticals, Inc. | Struthers Richard Scott | Director, Officer | SELL | $34.20 | 17,338 | $593,017 | 329,147 |
| 2025-03-22 00:31 | 2025-03-20 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $5.43 | 40,000 | $217,244 | 1,353,510 |
| 2025-03-22 01:44 | 2025-03-20 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | SELL | $31.06 | 9,578 | $297,491 | 72,850 |
| 2025-03-22 01:42 | 2025-03-20 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Director, Officer | SELL | $31.06 | 31,540 | $979,563 | 305,871 |
| 2025-03-22 01:40 | 2025-03-20 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Officer | SELL | $31.06 | 11,780 | $365,868 | 80,195 |
| 2025-03-22 01:36 | 2025-03-20 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | Officer | SELL | $31.06 | 7,778 | $241,583 | 97,130 |
| 2025-03-21 23:06 | 2025-03-19 | ZVRA | ZEVRA THERAPEUTICS, INC. | Bode John B | Director | BUY | $7.96 | 10,000 | $79,624 | 40,000 |
| 2025-03-22 01:38 | 2025-03-20 | RNA | Avidity Biosciences, Inc. | MacLean Michael F | Officer | SELL | $31.06 | 7,935 | $246,425 | 96,720 |
| 2025-03-22 04:00 | 2025-03-20 | WVE | Wave Life Sciences Ltd. | HENRY CHRISTIAN O | Director | OPT+S | $9.77 | 10,500 | $102,575 | 16,115 |
| 2025-03-21 23:01 | 2025-03-19 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $10.11 | 4,000 | $40,440 | 2,825,018 |
| 2025-03-22 03:00 | 2025-03-19 | IRON | Disc Medicine, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $54.02 | 52,429 | $2,831,989 | 187,297 |
| 2025-03-21 01:27 | 2025-03-17 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer | SELL | $17.61 | 1,200 | $21,137 | 928,914 |
| 2025-03-21 00:21 | 2025-03-20 | CLYM | Climb Bio, Inc. | Pimblett Emily | Officer | OPT+S | $1.31 | 1,199 | $1,571 | 15,130 |
| 2025-03-20 16:52 | 2025-03-17 | ZOM | Zomedica Corp. | Williams Rodney James | Director | BUY | $0.07 | 100,000 | $6,900 | 261,900 |
| 2025-03-20 23:53 | 2025-03-18 | BGNE | BeOne Medicines Ltd. | Wang Xiaodong | Director | OPT+S | $261.28 | 41,760 | $10,911,253 | 0 |
| 2025-03-21 01:12 | 2025-03-18 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $8.49 | 7,217 | $61,238 | 60,629 |
| 2025-03-21 01:05 | 2025-03-18 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $8.49 | 4,211 | $35,731 | 31,565 |
| 2025-03-21 01:27 | 2025-03-18 | EOLS | Evolus, Inc. | Beaver Sandra | Officer | SELL | $13.26 | 8,996 | $119,243 | 173,583 |
| 2025-03-21 01:27 | 2025-03-18 | EOLS | Evolus, Inc. | Yamagishi-Dressler Tomoko | Officer | SELL | $13.26 | 4,536 | $60,125 | 95,671 |
| 2025-03-21 01:27 | 2025-03-18 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $13.26 | 103,376 | $1,370,249 | 514,870 |
| 2025-03-21 01:15 | 2025-03-18 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | SELL | $8.49 | 19,289 | $163,673 | 139,346 |
| 2025-03-20 23:34 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | McCarthy Sean A. | Director, Officer | SELL | $0.60 | 37,656 | $22,556 | 995,195 |
| 2025-03-20 23:33 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | Officer | SELL | $0.60 | 8,551 | $5,122 | 201,026 |
| 2025-03-20 23:32 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Officer | SELL | $0.60 | 4,025 | $2,411 | 135,725 |
| 2025-03-20 23:31 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | BELVIN MARCIA | Officer | SELL | $0.60 | 19,512 | $11,688 | 248,636 |
| 2025-03-21 01:27 | 2025-03-18 | EOLS | Evolus, Inc. | Avelar Rui | Officer | SELL | $13.26 | 27,904 | $369,868 | 362,467 |
| 2025-03-20 23:05 | 2025-03-18 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $29.64 | 5,000 | $148,200 | 145,000 |
| 2025-03-20 23:30 | 2025-03-20 | ALZN | Alzamend Neuro Inc. | Horne William B. | Director | BUY | $0.98 | 5,000 | $4,892 | 26,666 |
| 2025-03-20 23:32 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | ROWLAND LLOYD A | Officer | SELL | $0.60 | 10,203 | $6,112 | 120,594 |
| 2025-03-21 01:11 | 2025-03-19 | UTHR | UNITED THERAPEUTICS Corp | PATUSKY CHRISTOPHER | Director | OPT+S | $310.72 | 5,000 | $1,553,585 | 900 |
| 2025-03-21 02:50 | 2025-03-18 | RNAC | Cartesian Therapeutics, Inc. | SPRINGER TIMOTHY A | Director, 10% owner | BUY | $15.26 | 89,863 | $1,371,157 | 8,621,325 |
| 2025-03-21 02:38 | 2025-03-19 | BMRN | BIOMARIN PHARMACEUTICAL INC | Burkhart Erin | Officer | SELL | $71.52 | 1,295 | $92,618 | 16,955 |
| 2025-03-21 01:15 | 2025-03-18 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | SELL | $13.58 | 14,020 | $190,392 | 8,078 |
| 2025-03-20 23:14 | 2025-03-19 | ANIP | Ani Pharmaceuticals Inc. | Davis Krista | Officer | SELL | $65.00 | 1,866 | $121,290 | 64,659 |
| 2025-03-19 23:47 | 2025-03-17 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $75.87 | 27,000 | $2,048,563 | 249,062 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.